Cargando…

HER-2 Immunohistochemical Expression in Bone Sarcomas: A New Hope for Osteosarcoma Patients

BACKGROUND: Osteosarcoma and chondrosarcoma, remain the most common primary bone tumours. Questions have been raised about the prognostic influence of HER-2 in bone sarcomas, but so far the results have been debatable. The her-2 expression is possibly a predictor of chemotherapy response. AIM: In th...

Descripción completa

Detalles Bibliográficos
Autores principales: Tabak, Sahar A., Khalifa, Sara E., Fathy, Yasmine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Republic of Macedonia 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6182517/
https://www.ncbi.nlm.nih.gov/pubmed/30337965
http://dx.doi.org/10.3889/oamjms.2018.318
_version_ 1783362582783983616
author Tabak, Sahar A.
Khalifa, Sara E.
Fathy, Yasmine
author_facet Tabak, Sahar A.
Khalifa, Sara E.
Fathy, Yasmine
author_sort Tabak, Sahar A.
collection PubMed
description BACKGROUND: Osteosarcoma and chondrosarcoma, remain the most common primary bone tumours. Questions have been raised about the prognostic influence of HER-2 in bone sarcomas, but so far the results have been debatable. The her-2 expression is possibly a predictor of chemotherapy response. AIM: In this study, we investigated the extent of HER-2 expression in bone sarcomas, and attempted to correlate it with pertinent variables that will help to provide better treatment options, especially for metastatic ones. MATERIAL AND METHODS: Fifty-two cases of bone sarcomas (32 osteosarcoma cases and 20 chondrosarcoma ones) were studied for HER-2 immunohistochemical expression then correlation with all available clinicopathologic features was done. RESULTS: Most of the osteosarcoma cases exhibited membranous staining (78.1%). Strong staining was observed (score 3+) in 34.4%; while 21.9% showed moderate staining (score 2+); and 21.9% displayed weak staining (score 1+), on the other hand, no staining was detected in 7 out of 32 cases (21.9%) (score 0). As regards chondrosarcoma, the absence of staining in all examined cases was noted. Immunohistochemical HER-2 overexpression correlated significantly with osteosarcoma site with P value = 0.004, with variation relating HER-2 intensity score to the site of osteosarcoma (P = 0.051). A statistically significant negative correlation was detected between HER-2 expression and the presence of metastasis at time of diagnosis (P = 0.006), A significant correlation was also found regarding HER-2 score and presence of metastasis with P value = 0.046 as more than half of cases with no metastasis at diagnosis (17/28 cases, 60.7%) showed positive intensity score. A statistically significant correlation was detected between HER-2 expression and patients’ age (P = 0.044). Also, HER-2 expression significantly correlated to histopathological detection of fibrous tissue, with P value = 0.033. Higher scores of HER-2 expression were associated with a significantly better differentiation (P = 0.038) since detection of wide areas of osteoid were associated with higher HER-2 scores. CONCLUSION: Further research would still be needed to delineate HER-2 role being a new hope for therapeutic targeting in bone sarcoma patients, mainly osteosarcoma in contrast to chondrosarcoma that didn’t express HER-2 at all.
format Online
Article
Text
id pubmed-6182517
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Republic of Macedonia
record_format MEDLINE/PubMed
spelling pubmed-61825172018-10-18 HER-2 Immunohistochemical Expression in Bone Sarcomas: A New Hope for Osteosarcoma Patients Tabak, Sahar A. Khalifa, Sara E. Fathy, Yasmine Open Access Maced J Med Sci Basic Science BACKGROUND: Osteosarcoma and chondrosarcoma, remain the most common primary bone tumours. Questions have been raised about the prognostic influence of HER-2 in bone sarcomas, but so far the results have been debatable. The her-2 expression is possibly a predictor of chemotherapy response. AIM: In this study, we investigated the extent of HER-2 expression in bone sarcomas, and attempted to correlate it with pertinent variables that will help to provide better treatment options, especially for metastatic ones. MATERIAL AND METHODS: Fifty-two cases of bone sarcomas (32 osteosarcoma cases and 20 chondrosarcoma ones) were studied for HER-2 immunohistochemical expression then correlation with all available clinicopathologic features was done. RESULTS: Most of the osteosarcoma cases exhibited membranous staining (78.1%). Strong staining was observed (score 3+) in 34.4%; while 21.9% showed moderate staining (score 2+); and 21.9% displayed weak staining (score 1+), on the other hand, no staining was detected in 7 out of 32 cases (21.9%) (score 0). As regards chondrosarcoma, the absence of staining in all examined cases was noted. Immunohistochemical HER-2 overexpression correlated significantly with osteosarcoma site with P value = 0.004, with variation relating HER-2 intensity score to the site of osteosarcoma (P = 0.051). A statistically significant negative correlation was detected between HER-2 expression and the presence of metastasis at time of diagnosis (P = 0.006), A significant correlation was also found regarding HER-2 score and presence of metastasis with P value = 0.046 as more than half of cases with no metastasis at diagnosis (17/28 cases, 60.7%) showed positive intensity score. A statistically significant correlation was detected between HER-2 expression and patients’ age (P = 0.044). Also, HER-2 expression significantly correlated to histopathological detection of fibrous tissue, with P value = 0.033. Higher scores of HER-2 expression were associated with a significantly better differentiation (P = 0.038) since detection of wide areas of osteoid were associated with higher HER-2 scores. CONCLUSION: Further research would still be needed to delineate HER-2 role being a new hope for therapeutic targeting in bone sarcoma patients, mainly osteosarcoma in contrast to chondrosarcoma that didn’t express HER-2 at all. Republic of Macedonia 2018-09-04 /pmc/articles/PMC6182517/ /pubmed/30337965 http://dx.doi.org/10.3889/oamjms.2018.318 Text en Copyright: © 2018 Sahar A. Tabak, Sara E. Khalifa, Yasmine Fathy http://creativecommons.org/licenses/CC BY-NC/4.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0).
spellingShingle Basic Science
Tabak, Sahar A.
Khalifa, Sara E.
Fathy, Yasmine
HER-2 Immunohistochemical Expression in Bone Sarcomas: A New Hope for Osteosarcoma Patients
title HER-2 Immunohistochemical Expression in Bone Sarcomas: A New Hope for Osteosarcoma Patients
title_full HER-2 Immunohistochemical Expression in Bone Sarcomas: A New Hope for Osteosarcoma Patients
title_fullStr HER-2 Immunohistochemical Expression in Bone Sarcomas: A New Hope for Osteosarcoma Patients
title_full_unstemmed HER-2 Immunohistochemical Expression in Bone Sarcomas: A New Hope for Osteosarcoma Patients
title_short HER-2 Immunohistochemical Expression in Bone Sarcomas: A New Hope for Osteosarcoma Patients
title_sort her-2 immunohistochemical expression in bone sarcomas: a new hope for osteosarcoma patients
topic Basic Science
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6182517/
https://www.ncbi.nlm.nih.gov/pubmed/30337965
http://dx.doi.org/10.3889/oamjms.2018.318
work_keys_str_mv AT tabaksahara her2immunohistochemicalexpressioninbonesarcomasanewhopeforosteosarcomapatients
AT khalifasarae her2immunohistochemicalexpressioninbonesarcomasanewhopeforosteosarcomapatients
AT fathyyasmine her2immunohistochemicalexpressioninbonesarcomasanewhopeforosteosarcomapatients